Innovation Forum 2022: Presentation of the HoloGRAFT cfDNA monitoring kit

/
Innovation Forum 2022: Presentation of the HoloGRAFT cfDNA monitoring kit

The new HoloGRAFT cfDNA dPCR monitoring kit, designed for the quantification of tiny amounts of cell-free DNA, serving as a biomarker of organ health in patients after solid organ transplantation, has been presented during the first-ever Innovation Forum virtual event. This webinar, organized by QIAGEN, focuses on the latest innovations in life sciences and offers exciting talks by expert scientists, among others on personalized cancer care, antibiotic resistance, mRNA vaccines or novel drug targets.

Read More

Omixon acquires Organ Monitoring Group BV

/
Omixon acquires Organ Monitoring Group BV

BUDAPEST, HUNGARY, June 4, 2022 /EINPresswire.com/

Omixon Biocomputing, Kft announced today that it has completed a collaborative agreement with Organ Monitoring Group to develop post-transplant monitoring product HoloGRAFT. As part of the agreement Omixon secured an exclusive option to acquire all remaining shares of Organ Monitoring Group BV (OMG) after having acquired 50% of OMG. Organ Monitoring Group BV owns some exclusive license rights to commercialize patented methods using copy-number-variant markers using digital polymerase chain reaction (dPCR) technology for transplant monitoring. The method was developed and validated by John Whitlam, MD, PhD, Clinical Lead, Kidney Transplantation at Austin Health, and colleagues at the Murdoch Children’s Research Institute in Melbourne, Australia. Omixon will fund collaborative development programs related to transplant monitoring applications while Mr Doug Bost, Founder and CEO of OMG, joins Omixon as Member, Board of Directors, and Vice-President of Transplant Monitoring Products. Financial details of the transaction were not disclosed.

Read More

JETA Molecular at EFI 2022 Congress in Amsterdam

/
JETA Molecular at EFI 2022 Congress in Amsterdam

JETA Molecular is participating at the upcoming EFI 2022 meeting held on May 17-20, 2022 in Amsterdam. We are looking forward to meeting our customers, business partners and friends at our booth nr. 15.

Results of our four-color genotyping and monitoring analyses using the QIAcuity Digital PCR System (QIAGEN) as well as data evaluating performance of QTRACE® (qPCR; relative quantification) and DigitalTRACE™ (dPCR; absolute quantification) in various EPT trials will be presented here:

Zamostna B., Mak C., Jiroutek P. and Bost D. (2022): A Four-color Digital PCR-based Method for Accurate DNA Genotyping and Sensitive Chimerism Analysis

Zamostna B., Mak C., Jiroutek P. and Bost D. (2022): External proficiency testing as a tool for evaluation
of the accuracy of relative and absolute quantification in chimerism analysis

Read More